Filing search / Centessa Pharmaceuticals plc / "Women"

PRE 14A

CNTA Centessa Pharmaceuticals plc

26 Apr 24

Preliminary proxy

4:36pm

for women diagnosed with ovarian cancer. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Scientific Officer of Abraxis

DEF 14A

u2u7h 5odc

23 May 22

Definitive proxy

8:00am

10-K

20sehu

30 Mar 22

Annual report

12:00am

8-K/A

EX-99.1

v8mivsg5twc04pg8

14 Mar 22

Unregistered Sales of Equity Securities

7:38am

8-K

EX-99.1

xht0d2v 3ooz

24 Feb 22

Unregistered Sales of Equity Securities

7:37am

8-K

EX-99.1

drjb5ff aepkild

14 Dec 21

Regulation FD Disclosure

7:58am

424B4

epb6dpl pv

1 Jun 21

Prospectus supplement with pricing info

4:07pm

S-1/A

moc3e135rr lyvj5

12 May 21

IPO registration (amended)

5:19pm

S-1

ep6fb

21 Apr 21

IPO registration

10:14am

DRS

f289m583jc 2y

15 Mar 21

Draft registration statement

12:00am